Meine Merkliste  

2.463 Aktuelle Fachpublikationen von Future Medicine



23.06.2014 | Pharmacogenomics, 2014

Pharmacogenomics May 2014, Vol. 15, No. 7, Pages 901-904.


Exploring effects of EAAT polymorphisms on cognitive functions in schizophrenia

23.06.2014 | Marco Spangaro; Marta Bosia; Andrea Zanoletti; Margherita Bechi; Buonocore Mariachiara; Adele Pirovano; Cristina Lor ..., Pharmacogenomics, 2014

Aim: To evaluate the effect of functional polymorphisms (rs4354668 and rs2731880) of the excitatory amino acid transporters (EAAT1 and 2) on the cognitive dysfunction that characterizes schizophrenia. Materials & methods: One hundred and ninety two subjects diagnosed with schizophrenia were ...


Replication of SULT4A1-1 as a pharmacogenetic marker of olanzapine response and evidence of lower weight gain in the high response group

23.06.2014 | Timothy L Ramsey; Qian Liu; Mark D Brennan, Pharmacogenomics, 2014

Aim: Antipsychotic efficacy biomarkers have the potential to improve outcomes in psychotic patients. This study examined the effect of SULT4A1-1 haplotype status (rs2285162 [A]-rs2285167 [G]) on olanzapine response. Patients & methods: We evaluated 87 olanzapine treated subjects from Phases 1, 1B ...


No association between genetic or epigenetic variation in insulin growth factors and antipsychotic-induced metabolic disturbances in a cross-sectional sample

23.06.2014 | Tim Moons; Marc De Hert; Gunther Kenis; Wolfgang Viechtbauer; Jim van Os; Henning Gohlke; Stephan Claes; Ruud van Winkel, Pharmacogenomics, 2014

Aim: Second-generation antipsychotics (SGA) are known to induce metabolic disturbances. Genetic pathways, such as the IGF pathway could be associated with increased metabolic syndrome (MetS). Additionally, IGF2 methylation varies as a function of environmental influences and is associated with ...


Diagnostic accuracy of HLA-B*57:01 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: a meta-analytic review

23.06.2014 | Sarah Cargnin; Claudio Jommi; Pier Luigi Canonico; Armando A Genazzani; Salvatore Terrazzino, Pharmacogenomics, 2014

Aim: To determine diagnostic accuracy of HLA-B*57:01 testing for prediction of abacavir-induced hypersensitivity and to quantify the clinical benefit of pretreatment screening through a meta-analytic review of published studies. Methods: A comprehensive search was performed up to June 2013. The ...


Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer

23.06.2014 | Geraldine Perkins; Camilla Pilati; Helene Blons; Pierre Laurent-Puig, Pharmacogenomics, 2014

In patients with metastatic colorectal cancer, overall survival has improved over the last decade mainly due to the use of effective targeted therapies such as anti-EGFR. However, survival improvement is linked to proper selection of patients expected to benefit from these treatments. KRAS codons ...


Pharmacogenetics in the treatment of chronic lymphocytic leukemia: what does the future hold?

23.06.2014 | Gillian G Johnson; Daniel F Carr; Munir Pirmohamed; Andrew R Pettitt, Pharmacogenomics, 2014

Pharmacogenomics May 2014, Vol. 15, No. 7, Pages 897-900.


Polymorphisms in translesion polymerase genes influence treatment outcome in malignant mesothelioma

23.06.2014 | Katja Goričar; Viljem Kovač; Vita Dolžan, Pharmacogenomics, 2014

Aim: We evaluated the influence of genetic variability in translesion polymerases REV1 and REV3L on the outcome of cisplatin treatment in malignant mesothelioma patients. Materials & methods: In total, 139 malignant mesothelioma patients were genotyped for seven tag SNPs in REV1 and REV3L. ...


Avatars of personalized cancer therapy can lead to a reduction in head and neck cancer survival disparities

17.06.2014 | Rafael Guerrero-Preston, Personalized Medicine, 2014

Personalized Medicine May 2014, Vol. 11, No. 3, Pages 243-246.


The pharmacogenomics of warfarin from the COAG and EU-PACT: where do we go from here?

17.06.2014 | Alan HB Wu; Harold Robert Superko, Personalized Medicine, 2014

Personalized Medicine May 2014, Vol. 11, No. 3, Pages 247-249.


Seite 3 von 247
Suche per e-Mail abonnieren

Sie erhalten passend zu Ihrer Suche die neusten Suchergebnisse per E-Mail. Dieser Service ist für Sie kostenlos und kann jederzeit abbestellt werden.

Ihr Bowser ist nicht aktuell. Microsoft Internet Explorer 6.0 unterstützt einige Funktionen auf Chemie.DE nicht.